{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:36Z","timestamp":1789469136830,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for patients with myelodysplastic syndromes (MDS). Despite evidence of comparable outcomes in selected older adults, disparities in HSCT utilization persist. This study analyzes trends, outcomes, and barriers such as age and insurance status associated with HSCT in MDS. We performed a retrospective analysis of the National Inpatient Sample (NIS) from 2016 to 2020 using ICD-10 codes to identify adult patients undergoing allogeneic HSCT. Patients were stratified according to MDS diagnosis. National estimates were calculated using discharge weights. Baseline characteristics and outcomes were compared using Pearson Chi-square and t-tests. Propensity score matching was used to adjust for potential confounders. Among 30,460 patients who underwent allogeneic HSCT, 4,980 (16.16%) had MDS. MDS patients were older (median age 62 vs. 49 years, p&lt;0.001) and had a higher burden of comorbidities, including chronic lung disease, diabetes, and hypertension (p&lt;0.001). They were more likely to be insured through Medicare (38.73% vs. 17.10%) and less likely to have private insurance (50.80% vs. 56.96%, p&lt;0.001). From 2016 to 2020, the proportion of HSCT performed in patients with MDS increased from 13.20% to 17.32% before a slight decline in 2020. MDS patients experienced in-hospital mortality (aOR 1.33, 95% CI 1.14\u20131.55), mechanical ventilation (aOR 1.30), neutropenic fever (aOR 1.20), and acute GVHD (aOR 1.26), but lower Clostridium difficile infection (aOR 0.75). MDS patients undergoing allogeneic HSCT are older, carry greater comorbidity burdens, and have worse in-hospital outcomes. Insurance disparities and age may continue to represent barriers despite increasing utilization. Further research is needed to optimize selection and peri-transplant care.<\/jats:p>","DOI":"10.1007\/s00277-026-07058-1","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:35:01Z","timestamp":1781249701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In-hospital mortality and complications are increased in hematopoietic stem cell transplant recipients with myelodysplastic syndromes"],"prefix":"10.1007","volume":"105","author":[{"given":"Aniket Vijay","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Sanjeevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Jose","family":"Idoate-Domench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diya Jayanth","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Palavilayil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Orakzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himal","family":"Kharel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hammad","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay Prabath","family":"Dronamraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"10","key":"7058_CR1","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","volume":"133","author":"U Platzbecker","year":"2019","unstructured":"Platzbecker U (2019) Treatment of MDS. Blood 133(10):1096\u20131107","journal-title":"Blood"},{"issue":"13","key":"7058_CR2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","volume":"129","author":"T de Witte","year":"2017","unstructured":"de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I et al (2017) Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 129(13):1753\u20131762","journal-title":"Blood"},{"issue":"3","key":"7058_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223\u201332","journal-title":"Lancet Oncol"},{"issue":"9","key":"7058_CR4","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/bmt.2013.51","volume":"48","author":"JR Passweg","year":"2013","unstructured":"Passweg JR, Baldomero H, Bregni M, Cesaro S, Dreger P, Duarte RF et al (2013) Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transpl 48(9):1161\u20131167","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"7058_CR5","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood-2013-07-515494","volume":"122","author":"N Kr\u00f6ger","year":"2013","unstructured":"Kr\u00f6ger N (2013) From nuclear to a global family: more donors for MDS. Blood 122(11):1848\u20131850","journal-title":"Blood"},{"issue":"1","key":"7058_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00277-014-2177-y","volume":"94","author":"M Oosterveld","year":"2015","unstructured":"Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A et al (2015) Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. Ann Hematol 94(1):23\u201334","journal-title":"Ann Hematol"},{"issue":"4","key":"7058_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1001\/jamaoncol.2019.5140","volume":"6","author":"E Atallah","year":"2020","unstructured":"Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M et al (2020) Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol 6(4):486\u2013493","journal-title":"JAMA Oncol"},{"issue":"7","key":"7058_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1182\/blood-2016-08-735076","volume":"129","author":"RH Moy","year":"2017","unstructured":"Moy RH, Huffman AP, Richman LP, Crisalli L, Wang XK, Hoxie JA et al (2017) Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood 129(7):906\u2013916","journal-title":"Blood"},{"issue":"7","key":"7058_CR9","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1080\/10428194.2022.2032034","volume":"63","author":"SY Goksu","year":"2022","unstructured":"Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA et al (2022) The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leuk Lymphoma 63(7):1651\u20131659","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"7058_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/bmt.2011.214","volume":"47","author":"NS Majhail","year":"2012","unstructured":"Majhail NS, Nayyar S, Santiba\u00f1ez ME, Murphy EA, Denzen EM (2012) Racial disparities in hematopoietic cell transplantation in the United States. Bone Marrow Transplant 47(11):1385\u20131390","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"7058_CR11","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1182\/bloodadvances.2023009765","volume":"7","author":"A Bashey","year":"2023","unstructured":"Bashey A, Zhang X, Morris LE, Holland HK, Bachier-Rodriguez L, Solomon SR et al (2023) Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors. Blood Adv 7(15):3816\u201323","journal-title":"Blood Adv"},{"issue":"10","key":"7058_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","volume":"15","author":"M Tomblyn","year":"2009","unstructured":"Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15(10):1143\u2013238","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"7058_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.31547\/bct-2022-002","volume":"5","author":"M Iida","year":"2022","unstructured":"Iida M, Liu K, Huang XJ, Depei W, Kuwatsuka Y, Moon JH, Dodds A, Wilcox L, Ko BS, Hamidieh AA, Ho KW, Ungkanont A, Ho A, Farzana T, Sim J, Man HV, Akter M, Abeysinghe P, Bravo MR, Gyi AA, Poudyal BS, Batshkh K, Srivastava A, Okamoto S, Atsuta Y, Registry Committee of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT) (2022) Trends in disease indications for hematopoietic stem cell transplantation in the Asia-Pacific region: a report of the Activity Survey 2017 from APBMT. Blood Cell Ther 5(4):87\u201398. https:\/\/doi.org\/10.31547\/bct-2022-002","journal-title":"Blood Cell Ther"},{"issue":"11","key":"7058_CR14","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.4065\/mcp.2010.0502","volume":"85","author":"A Tefferi","year":"2010","unstructured":"Tefferi A (2010) Myelodysplastic syndromes\u2013many new drugs, little therapeutic progress. Mayo Clin Proc 85(11):1042\u20135","journal-title":"Mayo Clin Proc"},{"key":"7058_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","volume":"34","author":"AM Zeidan","year":"2019","unstructured":"Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X (2019) Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev 34:1\u201315","journal-title":"Blood Rev"},{"issue":"16","key":"7058_CR16","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1200\/JCO.2010.34.1982","volume":"29","author":"BJ Averbook","year":"2011","unstructured":"Averbook BJ (2011) Mitotic rate and sentinel lymph node tumor burden topography: integration into melanoma staging and stratification use in clinical trials. J Clin Oncol 29(16):2137\u20132141","journal-title":"J Clin Oncol"},{"issue":"7","key":"7058_CR17","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbmt.2017.03.020","volume":"23","author":"BM Getta","year":"2017","unstructured":"Getta BM, Kishtagari A, Hilden P, Tallman MS, Maloy M, Gonzales P et al (2017) Allogeneic hematopoietic stem cell transplantation is underutilized in older patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 23(7):1078\u201386","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"7058_CR18","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1182\/bloodadvances.2020003726","volume":"5","author":"OB Lahoud","year":"2021","unstructured":"Lahoud OB, Devlin SM, Maloy MA, Roeker LE, Dahi PB, Ponce DM et al (2021) Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter\u2019s transformation. Blood Adv 5(14):2879\u201389","journal-title":"Blood Adv"},{"issue":"5","key":"7058_CR19","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1200\/JCO.2010.32.1919","volume":"29","author":"SA Giralt","year":"2011","unstructured":"Giralt SA, Horowitz M, Weisdorf D, Cutler C (2011) Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol 29(5):566\u2013572","journal-title":"J Clin Oncol"},{"issue":"4","key":"7058_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","volume":"371","author":"L Gragert","year":"2014","unstructured":"Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R et al (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371(4):339\u201348","journal-title":"N Engl J Med"},{"issue":"8","key":"7058_CR21","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2012-06-437343","volume":"121","author":"GE Switzer","year":"2013","unstructured":"Switzer GE, Bruce JG, Myaskovsky L, DiMartini A, Shellmer D, Confer DL et al (2013) Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood 121(8):1469\u20131476","journal-title":"Blood"},{"issue":"12","key":"7058_CR22","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.bbmt.2009.07.023","volume":"15","author":"KS Baker","year":"2009","unstructured":"Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK et al (2009) Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 15(12):1543\u201354","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"7058_CR23","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.bbmt.2010.09.006","volume":"17","author":"P Armand","year":"2011","unstructured":"Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT et al (2011) Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transpl 17(6):852\u2013860","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"7058_CR24","first-page":"9127","volume":"7","author":"YA Efebera","year":"2009","unstructured":"Efebera YA, Thandi RS, Saliba RM, Popat U, De Lima M, Alousi A, Hosing C, Rondon G, Champlin R, Giralt S (2009) The Impact of Pre-Stem Cell Transplant Ferritin Level on Late Transplant Complications: An Analysis to Determine the Potential Role of Iron Overload on Late Transplant Outcomes. Internet J Hematol 7(1):9127 PMID: 25356072; PMCID: PMC4209589","journal-title":"Internet J Hematol"},{"issue":"4","key":"7058_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41409-022-01896-z","volume":"58","author":"M Ramanathan","year":"2023","unstructured":"Ramanathan M, Kim S, He N, Chen M, Hematti P, Abid MB et al (2023) The incidence and impact of clostridioides difficile infection on transplant outcomes in acute leukemia and MDS after allogeneic hematopoietic cell transplant-a CIBMTR study. Bone Marrow Transpl 58(4):360\u2013366","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"7058_CR26","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1080\/21505594.2016.1250982","volume":"7","author":"Y Taur","year":"2016","unstructured":"Taur Y (2016) Intestinal microbiome changes and stem cell transplantation: lessons learned. Virulence 7(8):930\u2013938. https:\/\/doi.org\/10.1080\/21505594.2016.1250982","journal-title":"Virulence"},{"key":"7058_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1208044","volume":"14","author":"AH Asseri","year":"2023","unstructured":"Asseri AH, Bakhsh T, Abuzahrah SS, Ali S, Rather IA (2023) The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice. Front Pharmacol 14:1208044. https:\/\/doi.org\/10.3389\/fphar.2023.1208044","journal-title":"Front Pharmacol"},{"issue":"10","key":"7058_CR28","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.bbmt.2019.06.012","volume":"25","author":"K Paulson","year":"2019","unstructured":"Paulson K, Brazauskas R, Khera N, He N, Majhail N, Akpek G et al (2019) Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transpl 25(10):2086\u20132090","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"7058_CR29","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/bmt.2016.18","volume":"51","author":"D Niederwieser","year":"2016","unstructured":"Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y et al (2016) Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 51(6):778\u201385","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"7058_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41409-022-01667-w","volume":"57","author":"MM J\u00f6ris","year":"2022","unstructured":"J\u00f6ris MM, Schmidt AH, Bernas SN, Feinberg J, Sacchi N, Elmoazzen H et al (2022) Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-report from World Marrow Donor Association. Bone Marrow Transplant 57(6):1021\u20134","journal-title":"Bone Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07058-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:43:02Z","timestamp":1789465382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07058-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7058"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07058-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7023668\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"386"}}